Calquence approved in Japan for adults with treatment-naïve chronic lymphocytic leukaemia
Calquence significantly increased the time patients lived without disease progression or death vs. chemoimmunotherapy.AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL. The